NASDAQ:CLYM Climb Bio Q3 2024 Earnings Report $2.25 -0.15 (-6.25%) As of 09/12/2025 04:00 PM Eastern ProfileEarnings HistoryForecast Climb Bio EPS ResultsActual EPS-$0.13Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AClimb Bio Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AClimb Bio Announcement DetailsQuarterQ3 2024Date11/12/2024TimeAfter Market ClosesConference Call DateTuesday, November 12, 2024Conference Call Time9:30AM ETUpcoming EarningsClimb Bio's Q3 2025 earnings is scheduled for Tuesday, November 11, 2025, with a conference call scheduled at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Climb Bio Earnings HeadlinesClimb Bio to host webcast highlighting CLYM116, IgA Nephropathy opportunitySeptember 4, 2025 | msn.comClimb Bio to Host Webcast Highlighting CLYM116 and the IgA Nephropathy (IgAN) Opportunity on September 29, 2025September 4, 2025 | globenewswire.com2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematically extracting profits from the $4 billion that changes hands in crypto every single day. | Crypto Swap Profits (Ad)UPDATE – Climb Bio to Present at Upcoming September 2025 Investor ConferencesAugust 25, 2025 | globenewswire.comClimb Bio to Present at Upcoming September 2025 Investor ConferencesAugust 25, 2025 | globenewswire.comClimb Bio, Inc. (NASDAQ:CLYM) surges 12%; private equity firms who own 54% shares profited along with institutionsAugust 17, 2025 | finance.yahoo.comSee More Climb Bio Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Climb Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Climb Bio and other key companies, straight to your email. Email Address About Climb BioClimb Bio (NASDAQ:CLYM) Therapeutics, Inc. is a clinical-stage biotechnology company focused on the discovery and development of engineered protein therapeutics for the treatment of cancer and immune-mediated disorders. The company’s mission centers on designing biologics with enhanced specificity and functional activity to engage key cellular targets and improve patient outcomes in areas of high unmet need. At the heart of Climb Bio’s approach is its proprietary protein engineering platform, which combines mammalian cell display, directed evolution and computational modeling. This integrated system enables rapid identification, optimization and high-throughput screening of novel protein candidates, accelerating the transition from target validation to preclinical development while maintaining stringent quality and manufacturability criteria. Climb Bio has assembled a portfolio of preclinical programs that leverage its platform to generate next-generation biologics in immuno-oncology and related disease areas. The company is advancing these assets through lead optimization and IND-enabling studies, with a view toward first-in-human clinical trials. By focusing on modalities that can modulate immune responses and tumor microenvironments, Climb Bio aims to create differentiated therapeutic candidates with broad applicability. Headquartered in the greater Boston area, a major hub for life science innovation, Climb Bio operates dedicated research laboratories and maintains a leadership team with extensive experience in biopharmaceutical R&D and strategic partnerships. Looking ahead, the company plans to expand its pipeline through collaborations with academic institutions and industry partners, positioning its platform to address additional disease targets and serve global markets.View Climb Bio ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Celsius Stock Surges After Blowout Earnings and Pepsi DealWhy DocuSign Could Be a SaaS Value Play After Q2 EarningsWhy Broadcom's Q3 Earnings Were a Huge Win for AVGO BullsAffirm Crushes Earnings Expectations, Turns Bears into BelieversAmbarella's Earnings Prove Its Edge AI Strategy Is a WinnerWhat to Watch for From D-Wave Now That Earnings Are DoneDICKS’s Sporting Goods Stock Dropped After Earnings—Is It a Buy? Upcoming Earnings FedEx (9/18/2025)Micron Technology (9/23/2025)AutoZone (9/23/2025)Cintas (9/24/2025)Costco Wholesale (9/25/2025)Accenture (9/25/2025)NIKE (9/30/2025)PepsiCo (10/9/2025)BlackRock (10/10/2025)Fastenal (10/13/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
